OREANDA-NEWS. November 6, 2012. For 9M2012 revenue from sales of codeine-free Pentalgin®, Codelac® amounted to RUR 1,399.6 million with increase of 244.4% (RUR 993.2 million) compared with the same codeine-free products sales revenue of RUR 406.4 million for the previous year.

For 9M2012 revenue from sales of Pentalgin®, Codelac®, Terpincod® with codeine decreased by 64.2% (RUR 1,955.6 million) compared with the same codeine products sales revenue of RUR 3,047.8 million for the previous year.

For 9M2012 aggregate sales of Pentalgin®, Codelac®, Terpincod® included both in Rx and OTC product groups amounted to RUR 2,491.9 million with decrease of 27.9% (RUR 962.3 million) compared with RUR 3,454.3 million for the same period last year.The deviation of aggregate sales of three brands was mainly caused by decrease in sales of Terpincode®. For 9M2012 the sales of this pharmaceutical decreased by 27.9% (RUR 962.3 million) and amounted to RUR 276.6 million compared with RUR 930.5 million for the same period last year. Earlier the company reported it was not going to develop any substitutes of this pharmaceutical and was going to reimburse losses by rolling out new product range and increasing sales of the current one consisting of more than 250 pharmaceuticals.

For 9M2012 TPP sales increased by 35.0% (RUR 4,104.2 million) amounting to RUR 15,841.7 million compared with RUR 11,737.5 million for the same period last year.

For 9M2012 medical equipment sales increased by 48.1% (RUR 200.7 million) amounting to RUR 617.9 million compared with RUR 417.2 million for the same period last year. The increase in medical equipment segment was driven by goods range widening by means of sales of new goods through Pharmstandard-Medtechnika LLC due to the implementation of medical equipment sales joint project. The joint venture was established by DGM group and OJSC Pharmstandard in June 2011 in order to increase the sales of medical equipment designed for disinfection and sterilization.